Precision Health Clinical Trials

A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

Condition:   Biliary Cirrhosis, Primary
Intervention:  
Sponsor:   Target PharmaSolutions, Inc.
Recruiting - verified May 2017

The Circulating Cell-free Genome Atlas Study

Conditions:   Neoplasms;   Cancer
Intervention:  
Sponsor:   GRAIL, Inc.
Recruiting - verified April 2017

Pharmacogenomics of Warfarin in Hispanics and Latinos

Conditions:   Thrombosis;   Hemorrhage
Interventions:   Procedure: Cheek Swab/ Mouthwash sample;   Procedure: Blood Draw
Sponsor:   University of Arizona
Recruiting - verified November 2016

Expanded Noninvasive Genomic Medical Assessment: The Enigma Study

Conditions:   Down Syndrome;   Edwards Syndrome;   Patau Syndrome;   Klinefelter Syndrome;   Turner Syndrome;   DiGeorge Syndrome;   Chromosome Deletion;   Aneuploidy
Intervention:   Other: Blood sampling for Laboratory Developed Test (LDT) analysis
Sponsor:   Progenity, Inc.
Recruiting - verified May 2016

Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis

Conditions:   Glioblastoma;   Brain Metastases
Intervention:   Drug: ceritinib 750mg
Sponsors:   St. Joseph's Hospital and Medical Center, Phoenix;   Novartis;   Wayne State University;   Translational Genomics Research Institute
Recruiting - verified December 2016

A Phase 0 Study of AZD1775 in Recurrent GBM Patients

Conditions:   Glioblastoma;   GBM
Intervention:   Biological: AZD1775
Sponsors:   St. Joseph's Hospital and Medical Center, Phoenix;   The Ben & Catherine Ivy Foundation;   American Society of Clinical Oncology;   Barbara Ann Karmanos Cancer Institute;   Translational Genomics Research Institute, Phoenix, Arizona.
Recruiting - verified March 2016

Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic

Conditions:   Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions:   Other: cytology specimen collection procedure;   Drug: MEK 162 therapy or molecularly targeted therapy;   Procedure: therapeutic procedure;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
Sponsors:   Yale University;   National Cancer Institute (NCI)
Recruiting - verified November 2016

Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Conditions:   Adult B Acute Lymphoblastic Leukemia;   Adult T Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2017